Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:physicist
|
| gptkbp:associatedWith |
chronic myeloid leukemia
|
| https://www.w3.org/2000/01/rdf-schema#label |
Philadelphia chromosome
|
| gptkbp:involves |
ABL1
BCR |
| gptkbp:isA |
oncogenic driver mutation
|
| gptkbp:isActiveIn |
genetic testing
|
| gptkbp:isAssociatedWith |
survival rates
imatinib resistance splenomegaly cytogenetic abnormalities mutation analysis increased risk of transformation cytogenetic monitoring |
| gptkbp:isCharacterizedBy |
chromosomal translocation
translocation t(9;22)(q34;q11) |
| gptkbp:isConsidered |
prognostic assessment
treatment guidelines diagnostic_criteria_for_CML |
| gptkbp:isExaminedBy |
clinical trials
molecular diagnostics disease progression treatment response clinical trials for new drugs response to therapy |
| gptkbp:isFoundIn |
gptkb:acute_lymphoblastic_leukemia
adult population blast crisis CML leukemic cells |
| gptkbp:isInvolvedIn |
cell signaling pathways
therapeutic monitoring therapeutic decision-making |
| gptkbp:isLinkedTo |
clinical outcomes
treatment outcomes poor prognosis therapeutic resistance clinical management increased white blood cell count molecular heterogeneity mutation in ABL1 gene |
| gptkbp:isMaintainedBy |
karyotyping
bone marrow samples molecular cytogenetics peripheral blood samples |
| gptkbp:isPartOf |
CML diagnosis
CML pathogenesis leukemia classification |
| gptkbp:isProtectedBy |
PCR
FISH |
| gptkbp:isRelatedTo |
treatment strategies
hematological malignancies chronic phase CML |
| gptkbp:isStudiedIn |
cancer research
targeted therapy genomic research molecular mechanisms biomarker_development |
| gptkbp:isTrainedIn |
tyrosine kinase inhibitors
second-generation tyrosine kinase inhibitors |
| gptkbp:isUsedIn |
diagnosis of leukemia
|
| gptkbp:locatedIn |
1973
|
| gptkbp:resultedIn |
gptkb:BCR-ABL_fusion_protein
|